8-KEarnings & ResultsLeadership ChangesExhibits & Filings

Medtronic plc 8-K Report, Financial Results (Aug 19, 2025)

Filed August 19, 2025For Securities:MDT

Summary

Medtronic plc (MDT) has filed a Form 8-K detailing its first quarter fiscal year 2026 financial results, announced via press release on August 19, 2025. While the specific financial figures are not detailed within this 8-K filing itself but rather in the furnished press release (Exhibit 99.1), this report signals the company's performance update for the period ending August 2025. Investors should refer to the separate earnings release for critical financial metrics such as revenue, earnings per share, and segment performance. In addition to the financial update, the company announced a significant change to its Board of Directors. Effective August 19, 2025, the Board's size has been expanded from 11 to 13 members with the appointment of two new directors, John Groetelaars and William Jellison. Both new directors will receive standard non-employee director compensation, including cash retainers and equity grants, as per the company's policy. Mr. Jellison has been appointed to newly formed Growth and Operations committees, while Mr. Groetelaars will serve on the Growth committee. These board changes, announced via a separate press release (Exhibit 99.2), aim to bolster the board's oversight and strategic direction.

Key Highlights

  • 1Medtronic announced its first quarter fiscal year 2026 financial results via press release on August 19, 2025 (Exhibit 99.1).
  • 2The company expanded its Board of Directors from 11 to 13 members.
  • 3John Groetelaars and William Jellison were appointed as new directors, effective August 19, 2025.
  • 4Mr. Jellison has been appointed to the new Growth and Operations committees.
  • 5Mr. Groetelaars has been appointed to the new Growth committee.
  • 6New directors will receive standard compensation, including cash retainers and equity grants.
  • 7No reportable related-party transactions were disclosed for the new directors.

Frequently Asked Questions

This 8-K filing refers to a press release (Exhibit 99.1) for the detailed financial results of Medtronic's first quarter of fiscal year 2026. Investors should consult that press release for specific information on revenue, earnings per share, segment performance, and any forward-looking guidance.

The 8-K filing states the Board's size was increased from 11 to 13 members, appointing two new directors. While the specific strategic rationale for the expansion isn't detailed in the 8-K, the appointment of directors to newly created Growth and Operations committees suggests a focus on strengthening oversight and strategic direction in these key areas.

The 8-K filing does not provide detailed biographical information or professional backgrounds for John Groetelaars and William Jellison. Investors can typically find more in-depth information about new board members in the company's proxy statements or related press releases.

John Groetelaars and William Jellison, as non-employee directors, will be eligible to receive compensation in accordance with Medtronic's standard non-employee director compensation policy. This includes an annual cash retainer and a director equity grant, as further described in the company's Preliminary Proxy Statement.